Unlocking HIV-1: Can Natural Compounds Wake the Sleeping Virus?
"Exploring how naturally occurring substances might help eradicate HIV-1 by stimulating the expression of the integrated viral genome in chronically infected cells."
While highly active antiretroviral therapy (HAART) effectively suppresses human immunodeficiency virus (HIV) replication, it doesn't eliminate the virus from chronically infected cells. This means that when treatment is interrupted, the virus can rapidly rebound from these hidden reservoirs, including macrophages and resting memory CD4+ T-cells.
One promising strategy for HIV eradication involves using molecules that specifically induce the expression of the integrated HIV genome. This approach aims to make latently infected cells vulnerable to immune-mediated killing, while antiretroviral therapy prevents new infections. Cytokines like IL-2 and IL-7, and small molecules with pharmacological properties, are being explored for their ability to access viral reservoirs.
New research is exploring whether compounds such as 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM), nordihydroguaiaretic acid (NDGA), curcumin (Cur), and synthetic stigmasterol analogs can trigger HIV replication in chronically infected monocytic and lymphocytic cell lines.
Why HIV-1 Latency Matters
HIV-1 can persist in a latent state, creating a continuing challenge even when treatment suppresses active viral replication. This reservoir is an important obstacle to achieving a cure, but its size, distribution, and behavior can vary across individuals and experimental settings. Research therefore focuses not only on suppressing HIV-1, but also on understanding whether dormant virus can be safely reactivated and eliminated.
Treatment and Its Limits
Antiretroviral therapy is central to controlling HIV-1, but it does not remove every latently infected cell. One research strategy is latency reversal, in which dormant viral transcription is stimulated so infected cells may become visible to immune defenses or otherwise susceptible to elimination. The approach remains investigational because reactivation must be effective without causing harmful, broad immune activation.
From Suppression to Cure Research
HIV-1 research has progressed from controlling viral replication toward addressing the latent reservoir that persists during treatment. The recognition that dormant virus can remain despite antiretroviral suppression helped establish latency reversal as a possible component of cure research. This history has shaped current interest in targeted biological and chemical approaches, including natural compounds.
Natural Compounds Wake Up HIV-1 in Promonocytic Cells
The study focused on whether certain natural compounds could elicit HIV replication from Ul and H9+ cells, two chronically infected monocytic and lymphocytic cell lines. Researchers evaluated the cytotoxicity of natural compounds (CDM, NDGA, and Cur) and synthetic stigmasterol analogs 1 and 2 on uninfected and HIV-1 chronically infected cells using the Trypan blue dye exclusion method.
- CDM, NDGA, and Cur showed a dose-dependent activation of HIV-1 replication in Ul cells.
- No increase in p24 levels was observed in Ul cells when synthetic analogs 1 and 2 were added.
- CDM increased p24 production by approximately sevenfold.
- NDGA and Cur increased p24 production by nearly twofold compared with untreated control cells.
- Conversely, H9+ cells treated with any compound rendered lower levels of p24 antigen.
What Current Research Shows
Recent work on HIV-1 latency reversal examines how different agents can stimulate viral transcription and how those effects relate to reservoir reduction. The field is moving beyond simple reactivation measurements toward questions of selectivity, safety, and whether reactivated cells can actually be cleared. Natural compounds may therefore be relevant as candidate tools, but their value depends on evidence from appropriate cellular, animal, and clinical models.
The Reactivation Problem
An ideal latency-reversing agent would increase transcription from latent HIV-1 in vivo without producing the potentially harmful global T-cell activation associated with T-cell-receptor signaling. Many agents have reactivated HIV without general T-cell activation and have reached clinical trials, yet they have not eradicated the reservoir. Some clinical studies have reported reservoir reductions, but the available evidence still indicates that reactivation alone is insufficient for an HIV cure. The continuing challenge is to pair viral awakening with reliable clearance while maintaining tolerability.
Combination Strategies
Comparative testing reported in vitro cellular models and ex vivo primary-cell cultures from cART-treated HIV-positive aviremic patients identified bryostatin-1 plus JQ1 and ingenol-B plus JQ1 as potent combinations for reactivating latent HIV-1. The findings suggest that combining agents with different mechanisms may outperform single-agent approaches in selected models. However, these results describe viral reactivation potency in experimental systems and do not by themselves demonstrate reservoir eradication in people. The 2025 review repeats the identification of bryostatin-1 plus JQ1 and ingenol-B plus JQ1 as potent combinations.
Implications and Future Directions
The study's findings suggest that certain natural compounds can induce viral replication in latently HIV-1-infected promonocytic cells. This aligns with research on other natural compounds, like Ephedrae herba and Resveratrol, that have shown similar effects.
Seeing Latency in Greater Detail
Integrated single-cell multiomic analysis combines multimodal observations of latency reversal with methods that connect host-cell factors to viral gene expression. One reported study used integrated single-cell RNA-seq and ATAC-seq to profile the transcriptomic and epigenomic characteristics of approximately 4,000 latently infected cells after reactivation with three different latency-reversing agents. This approach is intended to clarify why some cells respond while others remain latent, strengthening the basis for more precise interventions.
Toward Targeted Cure Strategies
Future HIV-1 cure research will require a deeper understanding of how latency is established and maintained, as well as better models for testing reversal strategies. The shock-and-kill approach uses latency-reversing agents to reactivate HIV, with the goal of eliminating infected cells through virus-induced cytolysis or immune-mediated clearance. Reviews also emphasize the importance of small-animal models and contemporary cure approaches for translating mechanistic findings into practical interventions. Understanding latency remains critical to developing clinical technologies for reversal and cure.
Mechanisms, Models, and Combination Therapy
NF-κB signaling is being examined as a mechanistic target in HIV latency and reactivation, including its therapeutic potential and limitations. Current strategies increasingly consider how such pathways might be integrated into combination latency-reversal approaches aimed at durable HIV remission. Mathematical modeling is also being used to study regulatory factors and predict latency reversal, although recent reviews identify remaining gaps in these models. Together, these efforts show that HIV-1 latency is a systems-level problem rather than a single molecular switch.
From Laboratory Reactivation to Patients
Latently infected cells that persist during antiretroviral therapy are a major barrier to cure, making latency reversal relevant to people living with HIV-1 rather than only to laboratory research. One study assessed HIV-1 latency reversal with a multivalent HIV-1-derived virus-like particle in samples from 32 people living with HIV-1 in Uganda, the United States, and Canada who had begun combination antiretroviral therapy during chronic infection. Other work has directly examined viral rebound after treatment interruption across four patient cohorts, underscoring the clinical importance of controlling latent virus. These studies also show why promising reactivation findings must be evaluated for safety, durability, and real-world rebound risk.
The contrasting response observed in lymphocytic cells highlights the importance of cell type and the nature of chronic infection. It will require much additional work to understand the mechanisms responsible for p24 antigen induction by CDM, NDGA, and Cur.
These findings might be considered a relevant contribution to design efficient therapeutic strategies for attacking latent HIV reservoirs.